Market Cap 7.38M
Revenue (ttm) 0.00
Net Income (ttm) -30.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 174,700
Avg Vol 257,986
Day's Range N/A - N/A
Shares Out 3.03M
Stochastic %K 50%
Beta 0.00
Analysts Strong Sell
Price Target $2.00

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
BioPharm_Swinger
BioPharm_Swinger Jul. 28 at 2:17 PM
$INAB breaking out! All the indicators are there for a move to $4!
1 · Reply
FelixH86
FelixH86 Jul. 25 at 6:25 PM
$INAB close the week strong...2,45...
0 · Reply
Syyk
Syyk Jul. 25 at 1:19 AM
$ADAP 🚀 One of the Most Underrated Biotech Plays Out There? 🚀 ------Undervalued stock 1️⃣ Despite launching a commercial product and generating real revenue, Adap’s market cap is sitting at just $70M–90M. That’s insanely low for a company with fundamentals! 2️⃣ Lete-cel has received FDA Breakthrough Therapy Designation, and a BLA rolling submission is expected by Q4 2025. Major commercial milestones ahead! 3️⃣ Analyst consensus: Mostly BUY ratings, with price targets ranging from $1.40 to $1.70+. 📊 Q1 2025 (March quarter) revenue came in at $7.3M, up 28% YoY — showing strong post-launch stability. 💡 TTM revenue is now $179.6M, up a massive 195% YoY — growth is real and accelerating. 👩‍🔬 Backed by ~506 employees, strong manufacturing capabilities (27-day avg turnaround, 100% success rate), and the commercial launch of TECELRA, this isn’t just a biotech dream — it’s a company with substance. $INAB $PSTV $LIDR $IXHL
3 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 24 at 1:58 PM
0 · Reply
FelixH86
FelixH86 Jul. 24 at 1:39 PM
$INAB added...
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Jul. 23 at 8:20 PM
$INAB $4 is written all over this one when breaks out and volume comes in!
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 23 at 3:58 PM
$INAB Get in early PT $3 multi day play.
0 · Reply
jacksparo
jacksparo Jul. 23 at 3:46 PM
$INAB If this breaks 2.60 then a lot might get exited about it !!
0 · Reply
Boobooboo
Boobooboo Jul. 23 at 1:58 PM
$INAB 2.50 4.00
0 · Reply
dogood
dogood Jul. 23 at 11:58 AM
$FAMI all these are stuck after the reversal it, but they pulled it down $FAMI $CLRB $INAB should run back to $10 to $20 with great news
0 · Reply
Latest News on INAB
IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences


IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors


BioPharm_Swinger
BioPharm_Swinger Jul. 28 at 2:17 PM
$INAB breaking out! All the indicators are there for a move to $4!
1 · Reply
FelixH86
FelixH86 Jul. 25 at 6:25 PM
$INAB close the week strong...2,45...
0 · Reply
Syyk
Syyk Jul. 25 at 1:19 AM
$ADAP 🚀 One of the Most Underrated Biotech Plays Out There? 🚀 ------Undervalued stock 1️⃣ Despite launching a commercial product and generating real revenue, Adap’s market cap is sitting at just $70M–90M. That’s insanely low for a company with fundamentals! 2️⃣ Lete-cel has received FDA Breakthrough Therapy Designation, and a BLA rolling submission is expected by Q4 2025. Major commercial milestones ahead! 3️⃣ Analyst consensus: Mostly BUY ratings, with price targets ranging from $1.40 to $1.70+. 📊 Q1 2025 (March quarter) revenue came in at $7.3M, up 28% YoY — showing strong post-launch stability. 💡 TTM revenue is now $179.6M, up a massive 195% YoY — growth is real and accelerating. 👩‍🔬 Backed by ~506 employees, strong manufacturing capabilities (27-day avg turnaround, 100% success rate), and the commercial launch of TECELRA, this isn’t just a biotech dream — it’s a company with substance. $INAB $PSTV $LIDR $IXHL
3 · Reply
Picklerinthekitchen
Picklerinthekitchen Jul. 24 at 1:58 PM
0 · Reply
FelixH86
FelixH86 Jul. 24 at 1:39 PM
$INAB added...
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Jul. 23 at 8:20 PM
$INAB $4 is written all over this one when breaks out and volume comes in!
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 23 at 3:58 PM
$INAB Get in early PT $3 multi day play.
0 · Reply
jacksparo
jacksparo Jul. 23 at 3:46 PM
$INAB If this breaks 2.60 then a lot might get exited about it !!
0 · Reply
Boobooboo
Boobooboo Jul. 23 at 1:58 PM
$INAB 2.50 4.00
0 · Reply
dogood
dogood Jul. 23 at 11:58 AM
$FAMI all these are stuck after the reversal it, but they pulled it down $FAMI $CLRB $INAB should run back to $10 to $20 with great news
0 · Reply
Adamchristlover
Adamchristlover Jul. 23 at 3:27 AM
$OPEN $SLS $AKBA $VSTM $INAB Thank you Jack you saved me from losing big in this BS stock open. I appreciate the help man!
2 · Reply
MadMaverick
MadMaverick Jul. 22 at 3:12 PM
$RNXT - Late July Phase III data targeting pancreatic cancer, echoing recent biotech surges: 🔹 $INAB +150% on gene therapy news 🔹 $TCRT +80% after CAR-T trial update 🔹 $RDHL +58% after FDA feedback for trial 🔹 $PMN +145% after Fast Track Designation news Looking for a technical breakout from descending channel attracting swing traders https://chartingdaily.com/RNXT-stock Communicated Disclaimer - Do your own research too.
2 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 21 at 7:46 PM
$INAB All they are doing is proving relapse free survival in hard to treat cancers and the Street says it’s valued around 7 million 👌 #cancerZero
0 · Reply
jacksparo
jacksparo Jul. 21 at 7:35 PM
$OPEN People burned here and for no reason other than fomo. While they could have traded great stocks like $SLS $AKBA $VSTM Even $INAB is much better and about to move up again ⚡️✅⚡️!
2 · Reply
MoneyMikey
MoneyMikey Jul. 21 at 5:48 PM
0 · Reply
kadeee
kadeee Jul. 21 at 5:19 PM
$LGVN Wide awake now!! $PMN $ATNF $INAB
0 · Reply
kadeee
kadeee Jul. 21 at 2:53 PM
$LGVN I overslept and missed the pop. Hope she has juice left. $PMN $SABS $INAB
0 · Reply
KhalidsCapital
KhalidsCapital Jul. 19 at 2:27 AM
RSLS is the quiet kind of setup that blindsides the market. Merger confirmed. Micro float. No dilution cloud. Biotech names like this don’t need hype they just need a headline. By the time it’s trending, the easy money will already be made. $TCON $BIVI $INAB $DRMA
0 · Reply